Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Ceplene/IL-2 remission maintenance therapy has been shown to significantly prolong Leukemia
Free Survival in patients with Acute Myeloid Leukemia (AML) in first complete remission. This
is an international, multicenter, open-label study to evaluate the effects of remission
maintenance therapy with Ceplene/IL-2 in adult patients with AML in CR1 on specific immune
system cells (T and NK cells) and prospectively defined markers of immune response that are
known to reflect T and NK cell ability to combat AML.